SAM
Smithbridge Asset Management’s Edwards Lifesciences EW Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.19M | Buy |
15,255
+989
| +7% | +$77.4K | 0.21% | 72 |
|
|
2025
Q1 | $1.03M | Buy |
+14,266
| New | +$1.03M | 0.19% | 81 |
|
|
2024
Q3 | $864K | Buy |
13,086
+2,202
| +20% | +$145K | 0.15% | 103 |
|
|
2024
Q2 | $1.01M | Sell |
10,884
-167
| -2% | -$15.4K | 0.21% | 82 |
|
|
2024
Q1 | $1.06M | Buy |
11,051
+858
| +8% | +$82K | 0.22% | 83 |
|
|
2023
Q4 | $777K | Buy |
10,193
+411
| +4% | +$31.3K | 0.18% | 99 |
|
|
2023
Q3 | $678K | Buy |
9,782
+945
| +11% | +$65.5K | 0.17% | 104 |
|
|
2023
Q2 | $834K | Buy |
8,837
+437
| +5% | +$41.2K | 0.2% | 95 |
|
|
2023
Q1 | $695K | Buy |
8,400
+5,500
| +190% | +$455K | 0.17% | 101 |
|
|
2022
Q4 | $216K | Sell |
2,900
-7,700
| -73% | -$574K | 0.06% | 133 |
|
|
2022
Q3 | $876K | Buy |
10,600
+675
| +7% | +$55.8K | 0.36% | 67 |
|
|
2022
Q2 | $944K | Hold |
9,925
| – | – | 0.36% | 69 |
|
|
2022
Q1 | $1.17M | Buy |
9,925
+1,500
| +18% | +$177K | 0.39% | 67 |
|
|
2021
Q4 | $1.09M | Buy |
8,425
+250
| +3% | +$32.4K | 0.33% | 66 |
|
|
2021
Q3 | $925K | Buy |
8,175
+350
| +4% | +$39.6K | 0.31% | 70 |
|
|
2021
Q2 | $810K | Buy |
7,825
+300
| +4% | +$31.1K | 0.26% | 73 |
|
|
2021
Q1 | $629K | Buy |
7,525
+2,350
| +45% | +$196K | 0.27% | 60 |
|
|
2020
Q4 | $472K | Buy |
+5,175
| New | +$472K | 0.22% | 66 |
|